Blocking CXCR3 Prevents Immune Cells from Damaging the Aging Brain

Researchers identified that blocking the CXCR3 chemokine receptor prevents immune cells from infiltrating the brain through a compromised blood-brain barrier, a hallmark of aging and neurodegeneration. In mouse models of tauopathy, anti-CXCR3 treatment reduced harmful T cell accumulation in the brain, decreased neuronal damage, and improved cognitive function. This approach targets a specific pathway by which the body's immune response contributes to age-related brain decline.

The blood-brain barrier normally restricts immune cell entry into the central nervous system, but this protective mechanism deteriorates with age and in neurodegenerative conditions. When the barrier weakens, T cells from the body increasingly cross into brain tissue, where they trigger inflammatory responses that damage neurons. The CXCR3 receptor acts as a molecular guide system, helping activated T cells navigate toward and penetrate the brain by responding to chemical signals produced during chronic inflammation.

In experiments, researchers tested whether blocking this receptor could interrupt this damaging recruitment process. They used mouse models engineered to develop tau-related neurodegeneration, a hallmark of Alzheimer's disease. Treatment with anti-CXCR3 antibodies successfully reduced T cell accumulation in brain tissue, limited neuronal injury, and preserved cognitive abilities—suggesting the approach targets a specific mechanism linking immune dysfunction to age-related brain decline.